The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...
Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.
As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyret | ...
GlobalData on MSN5d
EC grants marketing authorisation to BridgeBio’s ATTR-CM treatmentThe European Commission (EC) has granted marketing authorisation to BridgeBio Pharma’s selective small molecule, acoramidis, ...
In other recent news, BridgeBio Pharma has made significant strides with its late-stage pipeline programs. The company's drug, Attruby, designed to treat ATTR-CM, a progressive fatal heart disease, ...
The company's drug, Attruby, designed to treat ATTR-CM, a progressive fatal heart disease, has seen substantial demand since its FDA approval, with 430 prescriptions written by 248 unique ...
The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in ...
The latest development follows the therapy’s approval under the name of Attruby by the US Food and Drug Administration in November 2024 to treat adults with ATTR-CM. "EC grants marketing authori ...
Palo Alto, California Thursday, February 13, 2025, 12:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback